Science and the world of drug discovery in particular has predominantly been two dimensional. Over the last decade there has been a drive to move into 3D models, organoids and whole organism screening in the aim to better understand the biology and reduce drug attrition. This webinar brings together experts from the field of academia and the biotech space as well as commercial vendors who can provide us with their insights to help us answer the question of 3D or not 3D?
Chair
Scott Cribbes
Business Development Director-EMEAI
Nexcelom
Speakers
Mara Tartari
HSO / Biology Project Lead Drug Discovery Scientist Cancer Therapeutics Unit at the Institute of Cancer Research
“Hetero-cellular models in High Throughput Screenings for Drug Discovery – Using phenotypes for target identification”
Professor Aline F. Miller BSC PhD FRSC FInstP
Chief Executive Officer and Founder Manchester Biogel
“Scaffold design to provide physiologically relevant 3D cultures for in vitro studies”
Stefan Grote
Research Assistant Department of Hematology and Oncology Children’s Hospital Tuebingen
